Press Release
Burlington, MA – April 21, 2008 –
HyperMed, Inc., the developer and manufacturer of hyperspectral diagnostic systems with application
in diabetic and vascular disease, today announces the appointment of Mark B. Carbeau as Director,
Chief Executive Officer, and President, effective immediately. Also, Mr. Daniel J. Levangie will
join the HyperMed Board of Directors, and serve as its non-executive Chairman.
Mr. Carbeau brings to HyperMed 25 years experience in building healthcare and medical technology companies.
He joins HyperMed from Kinetic Concepts Inc. (NYSE: KCI) where he was US President of the advanced wound care
business. In other operating roles, he was Vice President Corporate Development of OraPharma, Inc. during its
IPO in March of 2000 and prior to its sale to Johnson and Johnson in 2002, and held roles with Eli Lilly and
Company in sales, marketing and engineering. Mark has been an engagement manager with The Boston Consulting
Group, and a founding partner of a boutique consulting firm providing transaction support and interim management
to private equity clients. He holds a BS degree in Industrial Engineering from Penn State University and an
MBA from The Wharton School.
Mr. Levangie is the non-executive Chairman of the Board of Directors of eV3 Inc. (NASDAQ:EVVV). Beginning in
1992 Mr. Levangie was a member of the senior management team of Cytyc Corporation, a leading provider of surgical
and diagnostic products targeting women's health and cancer diagnostics. Most recently he served as President of
Cytyc's Surgical Products Division, Executive Vice President and a director of Cytyc Corporation. Following Cytyc
Corporation's merger with Hologic, Inc. in October of 2007, Mr. Levangie has remained as a director of Hologic, Inc.
Douglas Lind, MD, HyperMed director and Managing Partner at GBP Capital, HyperMed's primary investor, commented:
"We are extremely pleased to attract someone with Mark's experience to lead the Company at this phase of its commercial
expansion and rapid growth. Mark brings to HyperMed entrepreneurial spirit and a proven track record running a
publicly-traded, billion dollar enterprise. The addition of Dan Levangie as Chairman of the Board further adds world-class
industry experience, particularly in the development and commercialization of real-time tissue characterization devices."
About Hyperspectral Technology and HyperMed
Hyperspectral Technology combines advanced optics with sophisticated mathematical algorithms to identify subtle changes
in composition from reflected light. The technology was initially developed by the Department of Defense for use in aerial
espionage and satellite surveillance.
Its first medical application, HyperMed's OxyVu™, measures oxyhemoglobin and deoxy-hemoglobin to enable clinicians to
assess tissue metabolism, which may be predicative of tissue viability and health. The company's initial focus is on complications
of diabetes and peripheral arterial disease related to wound healing. Through a simple thirty-second non-invasive scan, a
physician gains valuable insights that aid in planning of advanced treatment interventions and surgery.
For more information about HyperMed and the OxyVu™ system, please visit the company's website at
www.hypermed-inc.com.
Press Contacts:
HyperMed, Inc.
Harriet Bridges
Marketing Manager
781-229-5900 x6019
hbridges@hypermed-inc.com
|
